A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
GK Activator (2)
Metformin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria: type 2 diabetic patients who have completed studies BM18248 or BM18249; patients considered by the investigator to be suitable for long term treatment with GK Activator (2). Exclusion Criteria: type 1 diabetes mellitus; women who are pregnant, breast-feeding or not using adequate contraceptive methods.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Outcomes
Primary Outcome Measures
AEs, laboratory parameters, ECG.
Secondary Outcome Measures
Mean change from original baseline in HbA1c, FPG, lipid profile.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00316758
Brief Title
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Official Title
A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
October 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This study will evaluate the long-term safety and tolerability of GK Activator (2) at doses ranging from 25mg - 100mg po bid, administered alone or in combination with metformin, in patients with type 2 diabetes. Eligible patients will be those who have completed study BM18248 (GK Activator (2) monotherapy) or BM18249 (GK Activator (2) and metformin); they will continue on the same treatment regimen (mono or combination therapy) as they received in the initial study. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
259 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
GK Activator (2)
Intervention Description
Escalating doses bid
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
As prescribed, in patients who were in study BM18249
Primary Outcome Measure Information:
Title
AEs, laboratory parameters, ECG.
Time Frame
Throughout study
Secondary Outcome Measure Information:
Title
Mean change from original baseline in HbA1c, FPG, lipid profile.
Time Frame
Throughout study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
type 2 diabetic patients who have completed studies BM18248 or BM18249;
patients considered by the investigator to be suitable for long term treatment with GK Activator (2).
Exclusion Criteria:
type 1 diabetes mellitus;
women who are pregnant, breast-feeding or not using adequate contraceptive methods.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Chula Vista
State/Province
California
ZIP/Postal Code
91910
Country
United States
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
City
West Hills
State/Province
California
ZIP/Postal Code
91307
Country
United States
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
City
Arkansas City
State/Province
Kansas
ZIP/Postal Code
67005
Country
United States
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
City
Binghamton
State/Province
New York
ZIP/Postal Code
13901
Country
United States
City
Fayetteville
State/Province
North Carolina
ZIP/Postal Code
28304
Country
United States
City
Statesville
State/Province
North Carolina
ZIP/Postal Code
28625
Country
United States
City
Winston-salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
City
Springdale
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
City
Beaver
State/Province
Pennsylvania
ZIP/Postal Code
15009
Country
United States
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
City
Federal Way
State/Province
Washington
ZIP/Postal Code
98003
Country
United States
City
Renton
State/Province
Washington
ZIP/Postal Code
98055
Country
United States
City
Camperdown
ZIP/Postal Code
2050
Country
Australia
City
Heidelberg
ZIP/Postal Code
3081
Country
Australia
City
Dimitrovgrad
ZIP/Postal Code
6400
Country
Bulgaria
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
City
Ruse
ZIP/Postal Code
7002
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1233
Country
Bulgaria
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 1M9
Country
Canada
City
London
State/Province
Ontario
ZIP/Postal Code
NGA 4V2
Country
Canada
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
City
Bammental
ZIP/Postal Code
69245
Country
Germany
City
Berlin
ZIP/Postal Code
10115
Country
Germany
City
Essen
ZIP/Postal Code
45355
Country
Germany
City
Giessen
ZIP/Postal Code
35385
Country
Germany
City
Görlitz
ZIP/Postal Code
02826
Country
Germany
City
Hamburg
ZIP/Postal Code
20249
Country
Germany
City
Kuenzing
ZIP/Postal Code
94550
Country
Germany
City
Nürnberg
ZIP/Postal Code
90402
Country
Germany
City
Tann
ZIP/Postal Code
36142
Country
Germany
City
Guatemala City
ZIP/Postal Code
01015
Country
Guatemala
City
Budapest
ZIP/Postal Code
1083
Country
Hungary
City
Gyor
ZIP/Postal Code
9024
Country
Hungary
City
Kecskemet
ZIP/Postal Code
6000
Country
Hungary
City
Chihuahua
ZIP/Postal Code
31238
Country
Mexico
City
Cuernavaca
ZIP/Postal Code
62270
Country
Mexico
City
Durango
ZIP/Postal Code
34070
Country
Mexico
City
Mexico City
ZIP/Postal Code
11650
Country
Mexico
City
Mexico City
ZIP/Postal Code
14050
Country
Mexico
City
Mexico City
ZIP/Postal Code
14610
Country
Mexico
City
Mexico-city
ZIP/Postal Code
06700
Country
Mexico
City
Bialystok
ZIP/Postal Code
15-276
Country
Poland
City
Gdansk
ZIP/Postal Code
80-757
Country
Poland
City
Gorzow
ZIP/Postal Code
66-400
Country
Poland
City
Krakow
ZIP/Postal Code
31-121
Country
Poland
City
Wroclaw
ZIP/Postal Code
50-088
Country
Poland
12. IPD Sharing Statement
Learn more about this trial
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
We'll reach out to this number within 24 hrs